Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders
作者:Peng Li、Qiang Zhang、Albert J. Robichaud、Taekyu Lee、John Tomesch、Wei Yao、J. David Beard、Gretchen L. Snyder、Hongwen Zhu、Youyi Peng、Joseph P. Hendrick、Kimberly E. Vanover、Robert E. Davis、Sharon Mates、Lawrence P. Wennogle
DOI:10.1021/jm401958n
日期:2014.3.27
We report the synthesis and structure–activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D2 receptors. This work has led to the discovery of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (ITI-007), which
我们报告了一类四环丁苯酮的合成与结构-活性关系,这些四环丁酮显示了对5-羟色胺5-HT 2A和多巴胺D 2受体的强结合亲和力。这项工作导致了4-((6b R,10a S)-3-methyl-2,3,6b,9,10,10 a -hexahydro -1 H,7 H -pyrido [3',4 ′:4,5]吡咯并[1,2,3- de ]喹喔啉-8-基)-1-(4-氟苯基)-丁-1-酮4-甲基苯磺酸盐(ITI-007),其有效值为5 -HT 2A拮抗剂,突触后D 2素和5-羟色胺转运蛋白的抑制剂。该多功能候选药物具有口服生物利用度,并且在体内表现出良好的抗精神病功效。目前,这种正在研究中的新药正在临床开发中,用于治疗神经精神疾病和神经疾病。